SG Americas Securities LLC cut its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART – Free Report) by 65.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 130,554 shares of the life sciences company’s stock after selling 249,675 shares during the period. SG Americas Securities LLC’s holdings in Integra LifeSciences were worth $1,230,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Global Retirement Partners LLC bought a new position in Integra LifeSciences in the fourth quarter worth about $25,000. Osaic Holdings Inc. grew its holdings in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth approximately $124,000. Institutional investors own 84.78% of the company’s stock.
Integra LifeSciences Stock Performance
Shares of NASDAQ IART opened at $18.05 on Friday. Integra LifeSciences Holdings Corporation has a 12-month low of $8.70 and a 12-month high of $18.92. The company has a market cap of $1.40 billion, a PE ratio of -2.79, a P/E/G ratio of 1.25 and a beta of 1.22. The stock has a 50 day simple moving average of $15.57 and a 200-day simple moving average of $12.68. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on IART. Wells Fargo & Company boosted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and upped their price target for the stock from $11.00 to $16.00 in a research report on Thursday, May 28th. Finally, Truist Financial dropped their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $16.20.
Check Out Our Latest Research Report on IART
About Integra LifeSciences
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
Featured Stories
- Five stocks we like better than Integra LifeSciences
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART – Free Report).
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
